bevacizumab-awwb Mvasi
Selected indexed studies
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. (Cancer Treat Rev, 2020) [PMID:32335505]
- Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. (Cancer Treat Rev, 2025) [PMID:40349571]
- Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. (Future Oncol, 2021) [PMID:34698523]
_Worker-drafted node — pending editorial review._
Connections
bevacizumab-awwb Mvasi is a side effect of
Sources
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. (2020) pubmed
- Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. (2025) pubmed
- MYL-1402O: A Bevacizumab Biosimilar. (2022) pubmed
- Bevacizumab-induced subungual hemorrhage. (2024) pubmed
- Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. (2021) pubmed
- Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer. (2023) pubmed
- Introduction by the Guest Editors: Bevacizumab. (2018) pubmed
- Safety of an Intravitreal Bevacizumab Biosimilar (MVASI). (2025) pubmed
- Bevacizumab: Zankapfel der Glioblastomtherapie. (2017) pubmed
- Targeting the microenvironment in the treatment of arteriovenous malformations. (2024) pubmed